Ascletis Pharma (HKG:1672) submitted an Investigational new drug application to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC.
The drug is intended for the treatment of obesity, a Wednesday bourse filing showed.
Ascletis Pharma (HKG:1672) submitted an Investigational new drug application to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC.
The drug is intended for the treatment of obesity, a Wednesday bourse filing showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.